Biotech News
Related news
OTLKOutlook2026-05-28 20:00 EST
Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
OTLKOutlook2026-08-13 01:45 EST
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
PRQRProQR Therapeutics2026-06-25 10:35 EST
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
IRIXIRIDEX2026-07-20 11:00 EST
Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering
MGTXMeiraGTx2026-04-16 11:48 EST
MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares
TARSTarsus Pharmaceuticals2026-08-06 11:02 EST
Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing
OCGNOcugen2026-05-04 20:01 EST
Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes
KPRXKiora Pharmaceuticals2026-04-07 11:00 EST
Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors
LENZLenz Therapeutics Inc2026-08-04 20:05 EST
LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026
LENZLenz Therapeutics Inc2026-06-24 12:30 EST
LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand
Outlook
Ophthalmic Bevacizumab Company Outlook Therapeutics develops and commercializes LYTENAVA, a bevacizumab formulation manufactured specifically for intravitreal administration in retinal diseases. The company is building a focused ophthalmology franchise around an approved alternative to repackaged bevacizumab originally produced for...
Recent company news
OTLKOutlook2026-08-14 11:15 EST
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
OTLKOutlook2026-08-13 01:45 EST
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
OTLKOutlook2026-08-12 20:01 EST
Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
OTLKOutlook2026-08-06 12:45 EST
Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026
OTLKOutlook2026-07-24 18:40 EST
Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD
Stock data
- Close
- 0.67 USD
- Market cap
- 120.89M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States